SXTPW
HEALTHCARE60 Degrees Pharmaceuticals, Inc. Warrant
$0.05-0.00 (-0.00%)LIVE
Live · NASDAQ · May 13, Close
AI Insight
What's Moving SXTPW Today?
No stock-specific AI insight has been generated for SXTPW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.03$0.16
$0.05
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume499
Avg Volume (10D)—
Shares Outstanding—
SXTPW News
20 articles- RedChip's Biotech Investor Conference Replays Now AvailableYahoo Finance·Apr 20, 2026
- 60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel WebsiteYahoo Finance·Apr 15, 2026
- 60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should KnowYahoo Finance·Apr 3, 2026
- Infrastructure Capital and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVYahoo Finance·Apr 2, 2026
- RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor ConferenceYahoo Finance·Apr 2, 2026
- 60 Degrees Pharmaceuticals Announces 2025 Annual ResultsYahoo Finance·Mar 31, 2026
- 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut ExtractYahoo Finance·Mar 18, 2026
- 60 Degrees Pharmaceuticals (SXTP) Partners With GoodRx to Expand Access to ARAKODAYahoo Finance·Feb 24, 2026
- 60 Degrees Pharmaceuticals Announces Third Quarter 2025 ResultsYahoo Finance·Nov 13, 2025
- 60 Degrees Pharmaceuticals and NDT Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVYahoo Finance·Oct 31, 2025
- 60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis StudyYahoo Finance·Oct 15, 2025
- 60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis StudyYahoo Finance·Oct 9, 2025
- Join 60 Degrees Pharmaceuticals' Exclusive Live Investor Webinar and Q&A Session on October 22Yahoo Finance·Oct 2, 2025
- Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVYahoo Finance·Sep 19, 2025
- 60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Sep 3, 2025
- 60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Aug 21, 2025
- 60 Degrees to commence Phase II babesiosis trial at Mount SinaiClinicaltrialsarena·Aug 20, 2025
- 60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic BabesiosisYahoo Finance·Aug 19, 2025
- 60 Degrees Pharmaceuticals Second Quarter 2025 Earnings: Revenues DisappointYahoo Finance·Aug 18, 2025
- 60 Degrees Pharmaceuticals Announces Second Quarter 2025 ResultsYahoo Finance·Aug 13, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$0.05
Day High$0.00
Day Low$0.00
52 Week High$0.16
52 Week Low$0.03
52-Week Range
$0.03$0.16
$0.05
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume499
Avg Volume (10D)—
Shares Outstanding—
About 60 Degrees Pharmaceuticals, Inc. Warrant
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company is headquartered in Washington, District of Columbia.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—